Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

Inclusion Criteria: * Must have histologic evidence of advanced myeloid leukemias defined as one of the following: primary refractory non-M3 AML; relapsed non-M3 AML; secondary AML; intermediate or poor prognosis de novo AML in patients who are \>= 60 years old * \>= 18 years of age * ECOG performance status of 0, 1 * Able to consume oral medication * Initial laboratory values: creatinine \<= 2.0 mg/dL; total or direct bilirubin \<= 1.5/dL; SGPT(ALT) \<= 3xULN; negative pregnancy test for women with child-bearing potential * Ejection fraction of \>= 45% Exclusion Criteria: * Subjects with FAM B3 * Must not be receiving chemotherapy (except Hydroxyurea) * Not receiving growth factors, except for erythropoietin * Subjects with a "currently active" second malignancy other than non-melanoma skin cancers * Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, MI within the last 6 months or uncontrolled cardiac arrhythmia * Subjects taking diltiazem * Subjects who require HIV protease inhibitors or those with AIDS-related illnesses * No evidence of cerebellar dysfunction at baseline or during prior cytarabine therapy * Not pregnant or breastfeeding * Uncontrolled infection * Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil, Tacrolimus